These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12124479)

  • 21. 153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.
    Knop S; Dohmen BM; Kanz L; Bares R; Einsele H
    Haematologica; 2004 Sep; 89(9):ECR36. PubMed ID: 15377488
    [No Abstract]   [Full Text] [Related]  

  • 22. Fast and robust adaptation of organs-at-risk delineations from planning scans to match daily anatomy in pre-treatment scans for online-adaptive radiotherapy of abdominal tumors.
    Gupta V; Wang Y; Méndez Romero A; Myronenko A; Jordan P; Maurer C; Heijmen B; Hoogeman M
    Radiother Oncol; 2018 May; 127(2):332-338. PubMed ID: 29526492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies.
    Blower PJ; Lam AS; O'Doherty MJ; Kettle AG; Coakley AJ; Knapp FF
    Eur J Nucl Med; 1998 Jun; 25(6):613-21. PubMed ID: 9618576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
    Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between myocardial counts and patient weight: adjusting the injected activity in myocardial perfusion scans.
    Notghi A; Williams N; Smith N; Goyle S; Harding LK
    Nucl Med Commun; 2003 Jan; 24(1):55-9. PubMed ID: 12501020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
    Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient specific treatment planning for systemically administered radiopharmaceuticals using PET/CT and Monte Carlo simulation.
    Grudzinski JJ; Yoriyaz H; Deluca PM; Weichert JP
    Appl Radiat Isot; 2010 Jan; 68(1):59-65. PubMed ID: 19879154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver Selective Internal Radiation Therapy with (90)Y resin microspheres: comparison between pre-treatment activity calculation methods.
    Bernardini M; Smadja C; Faraggi M; Orio S; Petitguillaume A; Desbrée A; Ghazzar N
    Phys Med; 2014 Nov; 30(7):752-64. PubMed ID: 24923844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.
    Lambert B; Bacher K; Defreyne L; Van Vlierberghe H; Jeong JM; Wang RF; van Meerbeeck J; Smeets P; Troisi R; Thierens H; De Vos F; Van de Wiele C
    Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):344-52. PubMed ID: 16333675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
    Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
    J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
    Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
    Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis.
    Vigna L; Matheoud R; Ridone S; Arginelli D; Della Monica P; Rudoni M; Inglese E; Brambilla M
    Phys Med; 2011 Jul; 27(3):144-52. PubMed ID: 20864370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki S; Strauss LG; Georgoulias V; Schuhmacher J; Haberkorn U; Karkavitsas N; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of mineralisation in the uptake of bone-seeking tracers.
    Leitha T
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1369. PubMed ID: 16830119
    [No Abstract]   [Full Text] [Related]  

  • 35. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
    Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anthropometric approaches and their uncertainties to assigning computational phantoms to individual patients in pediatric dosimetry studies.
    Whalen S; Lee C; Williams JL; Bolch WE
    Phys Med Biol; 2008 Jan; 53(2):453-71. PubMed ID: 18184999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative single photon emission computed tomography applied to a comparison of propanetetraphosphonate and albumin colloid for liver and spleen scintigraphy.
    Axelsson B; Jacobsson H
    Acta Radiol; 1988; 29(3):321-5. PubMed ID: 2968102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intra-arterial radionuclide therapy for liver tumours: effect of selectivity of catheterization and 131I-Lipiodol delivery on tumour uptake and response.
    Brans B; Bacher K; Vandevyver V; Vanlangenhove P; Smeets P; Thierens H; Dierckx RA; Defreyne L
    Nucl Med Commun; 2003 Apr; 24(4):391-6. PubMed ID: 12673167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.